Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG206 in advanced/metastatic solid tumors
NCT05614258Phase 1Active, not recruiting
- Sponsor
- Adagene
- Start
- Feb 2023
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADG206 in solid tumor (advanced stage) and metastatic solid tumors, sponsored by Adagene. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events and 3 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
ADG206
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT05614258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614258.